louisakewell, Author at European Medical Journal - Page 105 of 153

EMJ

Maintenance lapatinib after first-line chemotherapy in HER1/2-positive metastatic bladder cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles. MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University…

EMJ

Molecular signatures in breast cancer

At the 9th European Breast Cancer Conference (EBCC), Matti Aapro, MD, of Clinique de Genolier, Genolier, Switzerland, and Daniel Rea, MBBS, BSc, PhD…

EMJ

Phase 3 CheckMate 067 trial of nivolumab in untreated advanced melanoma

Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute, UK, disusses the results of the CheckMate 067 trial, a phase 3 trial of nivolumab…

EMJ

Neoadjuvant abiraterone acetate plus leuprolide acetate in localised high-risk prostate cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Eleni Efstathiou, MD, PhD, of The University of Texas MD Anderson Cancer Center…

EMJ

The place of the Oncotype DX® Breast Cancer Assay in clinical practice

Hope S. Rugo, MD, of UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, explains the Oncotype DX® Breast Cancer Assay and how it is…

EMJ

Dr Anne Armstrong and Prof Nigel Bundred discuss genomic profiling of breast cancer

Anne Armstrong, MRCP, PhD, MB ChB, BSc(Hons), of The Christie Hospital, Manchester, UK, and Nigel Bundred, MD, FRCS, of The University of Manchester, UK…

EMJ

Adjuvant therapy for early stage ER-positive, HER2-negative invasive breast cancer

Hope S. Rugo, MD, of UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, shares her experience on the recommended treatment approach…

EMJ

Phase 3 trial of fulvestrant with palbociclib for metastatic breast cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Nicholas Turner, MD, PhD, of the Institute of Cancer Research and Royal Marsden…

EMJ

ESC Congress 2015 Hot Lines to Reveal the Latest in CVD Research

Sophia Antipolis, 23 July 2015 – Six hot line sessions at ESC Congress 2015 are set to reveal the latest in cardiovascular disease research across a…

EMJ

Gilead Announces Phase 3 Results from the First Study to Evaluate Switching from TDF-Based Regimens to a TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide (E/C/F/TAF)

VANCOUVER, July 21, 2015 – Gilead Sciences, Inc. (NASDAQ: GILD) today announced detailed 48 week data from an open-label Phase 3 study (Study 109)…